Article Versions Notes

Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval J-B, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M, et al. PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine. 2022; 11(6):1734. https://doi.org/10.3390/jcm11061734

Teyssonneau, Diego, Antoine Thiery-Vuillemin, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé, and et al. 2022. "PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers" Journal of Clinical Medicine 11, no. 6: 1734. https://doi.org/10.3390/jcm11061734

Teyssonneau, D., Thiery-Vuillemin, A., Dariane, C., Barret, E., Beauval, J.-B., Brureau, L., Créhange, G., Fiard, G., Fromont, G., Gauthé, M., Ruffion, A., Renard-Penna, R., Mathieu, R., Sargos, P., Rouprêt, M., Ploussard, G., Roubaud, G., & on behalf of the CC-AFU, Cancerology Committee of the Association Française d’Urologie. (2022). PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers. Journal of Clinical Medicine, 11(6), 1734. https://doi.org/10.3390/jcm11061734